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MaGenome-wide association studies (GWAS) have been extensively used to study common complex diseases such as
coronary artery disease (CAD), revealing 153 suggestive CAD loci, of which at least 46 have been validated as having
genome-wide signiﬁcance. However, these loci collectively explain <10% of the genetic variance in CAD. Thus, we
must address the key question of what factors constitute the remaining 90% of CAD heritability. We review possible
limitations of GWAS, and contextually consider some candidate CAD loci identiﬁed by this method. Looking ahead, we
propose systems genetics as a complementary approach to unlocking the CAD heritability and etiology. Systems genetics
builds network models of relevant molecular processes by combining genetic and genomic datasets to ultimately identify
key “drivers” of disease. By leveraging systems-based genetic approaches, we can help reveal the full genetic basis of
common complex disorders, enabling novel diagnostic and therapeutic opportunities. (J Am Coll Cardiol 2015;65:830–45)
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AB BR E V I A T I O N S
AND ACRONYM S
CAD = coronary artery disease
eQTL = expression
quantitative trait locus
GGES = genetics of gene
expression studies
GWA = genome-wide
association
GWAS = genome-wide
association studies
GWNS = genome-wide
network studies
LDL = low-density lipoprotein
SNP = single-nucleotide
polymorphism
WES/WGS = whole-exome/
whole-genome sequencing
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831genome-wide signiﬁcant loci for complex diseases.
However, despite meta-analyses of many GWAS, the
overall contribution of identiﬁed loci to disease vari-
ation in the population is frequently <10%. In the cur-
rent review, we critically review GWAS, particularly
from the perspective of their possible limitations to
identify genetic factors that are environmentally
dependent. Using coronary artery disease (CAD) as
the example, we then propose that by integrating
existing GWA datasets with systems genetics ap-
proaches, we may have a path forward toward a
more complete understanding of complex diseases
including their heritability.
INTRODUCTION
GENETICS OF RARE SINGLE-GENE DISORDERS—THE
FOUNDATIONS OF THE SEARCH FOR HERITABILITY
OF COMMON DISORDERS. The heritability of traits
between generations is principally carried in de-
oxyribonucleic acid (DNA), mainly as single nucleo-
tide polymorphisms (SNPs), insertions, deletions, or
copy number variants. Another type of heritability,
believed to be independent of DNA (1,2), is carried by
epigenetic mechanisms, which are attributed with
inducing major shifts in DNA transcription (3). Epi-
genetics is not a topic of this paper, but has been
reviewed extensively elsewhere (4). In the case of
rare disorders, most carriers of 1 or more highly
penetrant risk variant develop the disease at some
point (Figure 1A). However, it is also common that
some persons carrying a potentially causative variant
will not develop that disorder; thus, the penetrance is
typically <100%. Penetrance is a time-dependent
aspect of phenotypic disease expression. For
example, both Huntington disease and cystic ﬁbrosis
are virtually 100% penetrant: cystic ﬁbrosis usually
soon after birth and Huntington disease by about 70
years of age. In contrast, familial breast cancer–asso-
ciated mutations in the BRCA1 gene have a lifetime
penetrance of 60% to 85%. That risk variants do not
necessarily lead to manifest disease in all carriers has
been highlighted as a possible path to identify genetic
and environmental mechanisms that confer resis-
tance to certain rare diseases (5). Mechanisms that
buffer against disease could be potential therapeutic
targets.
Despite the high penetrance of disease-causing
variants, rare diseases are, by deﬁnition, rare. As a
result of differences in genetic ancestry, the spectrum
and relative frequencies of disease-associated alleles
vary among different populations. For example,
cystic ﬁbrosis is most common in populations
originating from northern or western Europe(w1 in 2,000), whereas sickle-cell anemia is
more common in African or Afro-Caribbean
populations (w1 in 3,000). Through careful
characterization of symptoms and disease
phenotypes in families carrying rare disor-
ders, the causes of nearly one-half of the
estimated 7,000 single-gene disorders have
been identiﬁed, mainly by using markers
found at increased density across the genome
and by linkage analysis in pedigrees of
disease-carrying families (6). Although these
were key techniques in the discovery of
highly-heritable single-gene disorders that
typically only affect a limited number of
biological pathways and tissues, their scope
is inadequate for genetic studies of complex
disorders such as atherosclerosis and CAD,
where disease inheritance is blended with
environmental risk factors, and causative genes are
likely to be operative across several tissues (7).
GENETICS OF COMMON COMPLEX DISORDERS—
GENOME-WIDE ASSOCIATION STUDIES. The suc-
cessful identiﬁcation of the genetic causes and
mechanisms of many rare single-gene disorders
inspired scientists to use a similar approach to study
common complex disorders. Because such diseases
are widespread, linkage analysis within families was
not believed to be appropriate. Furthermore, it was
expected (and now conﬁrmed) that many genetic
signals underlie common complex disorders, each
with a relatively weak effect (e.g., odds ratio: <1.5). A
study design was instead chosen that analyzed
increasingly dense genomic markers in thousands of
mostly unrelated individuals in case-control associa-
tion studies. From these lines of argument, the GWAS
design was born (8).
One of the ﬁrst GWAS of CAD came from the
Wellcome Trust Case Control Consortium, which
discovered that the chromosome 9 locus was associ-
ated with CAD (9–11). Since then, 153 suggestive DNA
variants associated with CAD have been discovered
by GWAS, of which 46 were replicated in meta-
analyses of genome-wide association (GWA) datasets
(12). These CAD-associated loci are strikingly perva-
sive across the population, but generally have weak
effects. As recently reviewed (8), 50% of the CAD-
associated variants occur in over one-half of the
population, and at least 25% occur in over 75% of
the population. However, each variant usually con-
fers a minimal to modest increase in relative risk,
averaging only 18% (corresponding to an odds ratio of
1.18). A common theme of recent GWAS reviews is the
success of this approach, both for CAD and for other,
FIGURE 1 Development of Rare Versus Complex Disease, Using CAD as the Example
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(A) Rare disease does not develop in noncarriers of deoxyribonucleic acid (DNA) risk variants. The level of clinical manifestation varies with different rare diseases. Of
note, the indicated sigmoidal curve for rare disease development merely reﬂects that most biological events follow this growth pattern; it does not indicate that this true
for all rare diseases. (B) The development of complex diseases, such as coronary artery disease (CAD), generally follows a sigmoidal curve, characterized by a slow initial
growth phase (30 to 50 years), reaching a triggering level to enter a subsequent rapid expansion phase (10 years), and ﬁnally, a slow-down phase in which clinical
symptoms manifest. Subjects in genome-wide association studies (GWAS) are more likely to be deﬁned as cases or controls predominantly on the basis of early disease
processes, rather than due to later, largely overlapping processes. As a result, the likelihood of ﬁnding risk variants with genome-wide signiﬁcance is higher for disease
processes active in early CAD development. (C) Given the large overlap between cases and controls, increasing dependence of environmental contexts, and the shorter
duration of late disease processes, DNA variants regulating these processes are likely associated with disease at nominally-signiﬁcant p values in traditional analyses of
genome-wide association datasets.
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832more or less complex disorders, for which more than
1,000 loci have been identiﬁed (13). Certainly, the
sheer number of loci discovered, which has also
led to the discovery of many previously unknown
disease-causing genes, is a major success. Neverthe-
less, for most common complex disorders, the com-
bined contribution of these loci to disease variation in
the population is frequently <10%. Indeed, the 153
known CAD-associated variants explain <10.6% of
the likely genetic variation across the population (12).
Thus, w90% of the heritability of CAD, and of most
other common complex disorders, remains unex-
plained by identiﬁed GWA loci, despite the inclusion
of remarkably large numbers of subjects: a recent
meta-analysis of several GWAS for CAD comprised
63,746 cases and 130,681 controls (12). Although a
GWAS-based approach will clearly not reveal the fullextent of the heritability of CAD and other common
complex disorders, more complete sequencing tech-
niques, particularly expanded whole-exome/whole-
genome sequencing (WES/WGS), typically applied to
the same case-control cohorts previously used in
GWAS, promise to reveal additional rare risk variants,
perhaps with larger effects on heritability (14). These
results and additional reﬁnements of the analysis of
existing GWAS (14) will contribute to reducing the
large fraction of missing heritability, but to what
extent?
When addressing the “missing heritability” it is
also reasonable to question the reliability of CAD
heritability estimates. Because the overall fraction of
genetic variance in CAD is less than we believe, is
missing heritability largely (w90%) exaggerated?
From traditional analysis of family pedigrees in
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833twins, the range of genetic variance in CAD is be-
tween 40% and 60% (15). Assuming 40% heritability,
the 153 genome-wide signiﬁcant SNPs explain 10.6%
of CAD variability. Another way of assessing herita-
bility using GWA datasets is to consider all measured
SNPs (16). When applying this “polygenic” model to
the complex trait of height, 294,831 SNPs were found
to explain as much as 45% of height variance (16). The
authors concluded that because individual effects
are too small to pass the stringent signiﬁcance tests
(p < 108) traditionally used in GWAS, most height
heritability is not “missing,” but has simply not been
detected in the GWA data. Thus, the range of 40% to
60% CAD heritability is probably reasonable. How-
ever, the notion of completely independent genetic
and environmental risk factors needs reconsidera-
tion, as most genetic risk factors increasingly appear
to be dependent on environmental inﬂuences (17).
GENETICS OF COMMON COMPLEX DISORDERS—
THE SEARCH FOR MISSING HERITABILITY. Some of
the missing heritability of CAD and other common
complex disorders is likely carried by rare variants
that may be identiﬁed in ongoing WES/WGS projects
(as opposed to the relatively common variants
discovered to date in GWAS [18]). In addition, epige-
netic mechanisms will likely carry an as yet unknown
fraction of complex disease heritability (4). Although
deﬁning the role of epigenetic mechanism requires
other techniques, and despite ambiguity regarding
how epigenetic modiﬁcations remain conserved
across generations (1), these sources will undoubtedly
reduce the fraction of missing heritability. Will they
provide the full picture? Or are there fundamental
problems with how we have been trying to under-
stand and therefore seek heritability for complex
traits? We believe this may be the case and that it
is timely to critically review our understanding
of complex disease inheritance by more carefully
investigating how genetic risk variants interact with
environmental factors to cause disease.
In this review, we question the notion that the
heritability of common complex disorders is best
revealed by traditional analyses of DNA sequence
data in isolation, as thus far performed in GWAS and
WES/WGS projects. Sequential analyses of DNA vari-
ants in these studies results in an overwhelming
multiple-testing problem, and it can be questioned
whether simply making the case-control cohorts
larger to enable smaller differences to become
genome-wide signiﬁcant is the only reasonable path
to follow. We also critically appraise the potential
importance of identiﬁed risk loci by examining the
suggested roles of their putative candidate genes indisease development. Using CAD development as an
example, we suggest that genome-wide signiﬁcant
risk loci most likely underlie an early and protracted
phase of CAD development, but are unlikely to regu-
late the rapid or late phases of CAD development that
culminate in clinical events (Figure 1B). We instead
believe that there may be a more important subpop-
ulation of risk variants, which exert their effects on
CAD only in certain environmental contexts. The
context-dependence of this risk variant subpopula-
tion is likely to render itself nominally signiﬁcant
(p < 0.05) (Figure 1C) in traditional analyses of GWA
datasets considering DNA variants in sequence, but
it would fail to reach genome-wide signiﬁcance
(p < 108) (Figure 2) (17). To grasp these assumptions,
it is vital to understand how complex diseases
develop. In the following section, we evaluate
atherosclerosis and plaque development from the
perspective of the likely timing and pathogenesis of
genetic effects in CAD.
ATHEROSCLEROSIS DEVELOPMENT CULMINATING
IN CLINICAL MANIFESTATIONS—MYOCARDIAL
INFARCTION AND STROKE. Generally, diseases are
believed to develop according to a sigmoidal
(S-shaped) curve (19): commencing slowly with a
positive acceleration phase; then increasing rapidly,
approaching an exponential growth rate as in a
J-shaped curve; and ﬁnally, saturating, stabilizing
at a near-zero growth rate.
The development of atherosclerotic lesions in the
coronary tree generally agrees with this S-shaped
model, although the ﬁnal phase of plaque develop-
ment and progression may be variable and can
include further progression (Figure 1B) (20). The
notion that atherosclerosis develops slowly over a
very long period, followed by more rapid progression,
is supported by studies in mice (21,22) and humans
(23,24). Brieﬂy, early atherosclerotic lesions develop
slowly, over 20 to 30 weeks in mice and probably over
30 to 40 years in humans, starting in adolescence
(Figure 1B). Atherogenesis involves retention of
circulating plasma lipoproteins, mainly low-density
lipoprotein (LDL), at sites of turbulent blood ﬂow.
Some LDL particles remain and are modiﬁed by redox
processes in the subendothelial space. Oxidized LDL
subtly activates the endothelium, primarily by
expressing adhesion molecules, which induce trans-
endothelial migration of leukocytes, predominantly
monocytes. Upon entering the subendothelial space
and the intima, monocytes differentiate into macro-
phages, which take up oxidized LDL particles, initi-
ating a key process of atherosclerosis: foam cell
formation. As lipid-laden foam cells accumulate
FIGURE 2 Risk Variants Identiﬁed in GWAS
Genome-wide significant (”GWA hits”) <10–8
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dependence Penetrance Effect
Mode of
Discovery
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(A) The blue triangle represents all DNA variants tested for CAD association in GWAS. The 5% (salmon triangle) have nominal signiﬁcant
association (p < 0.05). The very top of the central salmon triangle consists of risk variants associated with CAD at a level of genome-wide
signiﬁcance (p < 108). The middle section consists of risk variants associated with CAD at a level suggestive of genome-wide signiﬁcance
(p < 105). The base of the triangle consists of risk variants associated with CAD at a level of nominal signiﬁcance (p < 0.05). On the right,
the likely inﬂuences of different signiﬁcance levels on context dependency, penetrance, and disease are indicated. On the far right is the
likely mode of discovery for testing genome-wide signiﬁcance (p < 108). DM ¼ diabetes mellitus; GWA ¼ genome-wide association;
GWES ¼ genome-wide network studies; other abbreviations as in Figure 1.
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834in the intima, fatty streaks appear as the ﬁrst
histologically-visible manifestation of atheroscle-
rosis. This early phase of atherosclerosis develop-
ment ends when foam cells within the fatty streaks
start to aggregate, forming small atherosclerotic
plaques with well-deﬁned borders (21).
In the second phase, the small plaques expand
rapidly, both across the arterial wall and, impor-
tantly, into the lumen of the artery, where they can
compromise blood ﬂow. The expansion phase is rapid
(w10 weeks) in mice, and evidence from 14C dating of
human atherosclerotic plaques (23) suggests that it is
also rapid (relative to lifespan) in humans (<10 years
before clinical symptoms).
In the third and ﬁnal phase, plaque biology can be
quite variable, with approximately 30% of lesions
showing rapid progression over 12 months to become
ﬁbroatheromas, with a lipid-rich core encapsulated
by either a thin (10%) or thick cap (20%). Thin-cap
ﬁbroatheromas are considered the most unstable le-
sions and the most likely to lead to acute myocardialinfarction. Over the subsequent 12 months, 75% of
thin-cap ﬁbroatheromas stabilize, whereas 5% of
thick-cap ﬁbroatheroma develop high-risk features
(20,25). Furthermore, depending on its location, a
mature plaque can have dramatic or minimal effects
on blood ﬂow, possibly leading to angina caused by
myocardial ischemia of the heart muscle subtended
by the plaque-narrowed artery.
A complex interplay of factors inﬂuences whether
or not an advanced plaque ruptures, including: the
extent and degree of lipid-core necrosis sustained
by proliferating macrophages within the plaque; de
novo monocyte migration/emigration; the degree of
luminal stenosis; plaque burden; positive (outward)
vessel remodeling; and the thickness of the ﬁbrous
cap (26). Rupture of a coronary plaque leads to in-
tracoronary thrombus formation, which may or may
not occlude the vessel. Although a nonocclusive
thrombus may increase luminal narrowing and hasten
lesion progression, an occlusive thrombus is associ-
ated with reduced myocardial perfusion that typically
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835causes an acute coronary syndrome (myocardial
infarction or unstable angina) or sudden death.
GWA LOCI FOR COMMON COMPLEX DISEASES—
HOW IMPORTANT ARE THEY?
Genome-wide signiﬁcant loci identiﬁed by GWAS
conducted for complex diseases may fail to identify
central pathological processes and corresponding key
DNA variants that contribute to heritability. This
notion rests primarily on 3 conventions about the
development and phenotypic expression of complex,
relatively rare diseases (Figures 1A and B).
1 . The case/contro l over lap . In comparing cases
with population controls in studies of complex
diseases (as opposed to rare diseases) (Figures 1A
and B), overlap in central disease processes is
inevitable, as these processes may be active
without having caused clinical symptoms in the
control subjects. Consequently, many DNA vari-
ants regulating genes active in these processes will
not surface at a level of genome-wide signiﬁcance
in GWAS. However, due to a likely over-
representation of these processes within cases
(albeit not unique), DNA variants regulating these
processes will likely instead present in GWAS with
nominally signiﬁcant p values.
2 . The context of sh i f t ing env i ronments . DNA
variants that regulate genes active in central dis-
ease processes, and which do so independently of
changing environmental contexts, are likely to
surface with genome-wide signiﬁcance in GWAS.
In contrast, DNA variants that depend on pre-
existing environmental contexts to regulate
genes in central disease processes are unlikely to
surface with genome-wide signiﬁcance in GWAS. A
principal reason is that many of these contexts are
variably present (active), probably resulting in
context-dependent risk variants presenting with
nominally-signiﬁcant disease associations in
GWAS (Figure 1C). Contexts presenting at the
macroenvironmental level in CAD are mainly
lifestyle factors (smoking, diet, and sedentary
lifestyle) or other major disease risk factors such as
obesity, diabetes, hypertension, and certain in-
ﬂammatory diseases. Such factors can be consid-
ered in GWAS (27), but most have not yet been
accounted for. Other macroenvironmental factors,
like highly stressful events (such as death of a
spouse or natural disaster) (28,29) also predispose
to myocardial infarction, but are harder to deﬁne
(and thus to consider) in the individual patient.
Macroenvironmental factors inevitably result in
alteration of a wide array of microenvironmentsspeciﬁc to tissues and cell types. The microenvi-
ronment in a given cell or tissue is the ﬁnal
determinant of whether a context-dependent DNA
variant will be active (affecting gene activity) or
not. Take inﬂammation as an example of a variable
microenvironmental context. When early “fatty
streak” lesions develop into plaques with intact
borders, intralesional foam cells are believed to
initiate inﬂammatory gene activation, which sub-
sequently causes the rapid expansion phase of
lesion growth (21,22). Previously silent DNA vari-
ants that speciﬁcally affect the activation of these
inﬂammatory genes will now be suddenly relevant
to disease progression, only to again become silent
(or less active) in the late phase of lesion devel-
opment. There are many reasons why a DNA
variant can have changing effects on the genes it
regulates—the most obvious being that the genes
regulated by a given DNA variant may, during
early phases of disease development, be largely
silent (not expressed, as exempliﬁed with inﬂam-
matory genes). A more complex reason is that a
microenvironmental context (e.g., inﬂammatory
stimulation) activates a speciﬁc cotranscription
factor whose binding and effect depend on a given
allele of a DNA variant. In this scenario, the
microenvironmental perturbation (that is, inﬂam-
mation) is needed for the regulatory effect of the
DNA variant. Context-dependency of gene
expression in this fashion has experimentally been
shown to be both common and strong (30–33).
3. The context of t ime. DNA variants that regulate
genes in central disease processes that are active
(relevant) over a long period are more likely to
surface with genome-wide signiﬁcance, those that
regulate disease processes over a short period
(e.g., late in disease development). This is in part
related to point 2, because DNA variants that
depend on shifting environments for their effect
on disease processes also are likely to affect the
disease over a shorter time period.
Taking these 3 conventions together, we suspect
that DNA variants identiﬁed as having genome-wide
signiﬁcance by GWAS are likely to regulate early dis-
ease processes in the slow initial growth phase, rather
than those in the rapid growth or late phases
(Figure 1B). In CAD development, for example, this
assumption is partly based on the following devel-
opmental characteristics. First, the pathobiology of
early CAD development is likely more genetically
driven than the later phases and is less affected by
environmental exposures linked to later life stages,
like diabetes, hypertension, obesity, sedentary life-
style, and inﬂammatory states (all less prevalent in
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836adolescence and the early adult years). Also, as the
ﬁrst and longest phase of CAD development, the
inclination of the curve of the slow phase will be
highly decisive for how case and control subjects are
deﬁned in GWAS (Figure 1C). Conversely, the most
signiﬁcant disease-associated DNA variants, deﬁned
by comparing case and control subjects (genome-
wide signiﬁcant variants), will likely point toward
genes active in the early phase. In contrast, the late
and rapid phases are driven more by disease pro-
cesses that are often shared between case and control
subjects (e.g., obesity, hypertension, dyslipidemia,
and diabetes) and that are more inﬂuenced by envi-
ronmental factors compared with the early phase.
Thus, DNA variants affecting later CAD phases are
more likely to be context-dependent. Adding to the
complexity of the later phases is that they commonly
involve many other parallel disease processes acting
across several organs. For CAD, these organs are pri-
marily metabolic (e.g., the liver and pancreas with
diabetes, adipose tissue with obesity, or systemic
immune activation). Thus, although late processes
likely involve additional systemic contributions
linked to context-dependent DNA variants that are
unlikely to be explained by genome-wide signiﬁcant
loci detected by GWAS, early processes are more
likely to be genetically driven and exposed to fewer
confounding factors, and therefore, are more likely
to contain regulatory DNA variants of genome-wide
signiﬁcance.
Multiple ongoing studies seek to better understand
the mechanisms of the 46 genome-wide signiﬁcant
loci thus far identiﬁed by GWAS for CAD, and whether
they relate to early or late events in CAD development
(7). If (as we suspect) most of these CAD loci (and loci
for other complex diseases that develop in a similar
fashion) are related to early events in disease devel-
opment, their clinical usefulness may be limited
primarily to guiding preventive measures and,
possibly, to developing therapies against early dis-
ease development (primary prevention). Conversely,
the usefulness of these ﬁndings for secondary pre-
vention, to prevent the rapid and late phase of CAD
development, would be restricted.
To test the assumption that DNA variants with
genome-wide signiﬁcance mainly regulate early CAD
development, we examined candidate genes assigned
to CAD GWA loci (12). Of the 50 candidate genes
proposed for 46 loci conﬁrmed in a meta-analysis of
GWA datasets, 10 are involved in regulating plasma
lipid levels (7 for LDL, 1 for high-density lipoprotein,
and 2 for triglycerides) (8). Plasma lipids are primarily
of importance for driving early atherosclerosis
development, consistent with the notion that lociidentiﬁed by GWAS will be more useful for primary
prevention and with the experimental ﬁnding
that atherosclerosis regression in response to LDL
lowering is much greater for early lesions than for
mature and advanced lesions (22). An additional 6
candidate genes are involved in hypertension, which
is clearly important for early endothelial activation;
however, its importance for later phases of CAD is less
clear. In fact, the guidelines for hypertension treat-
ment in the elderly (>60 years of age) were recently
altered; the blood pressure goal has now been eased
to <150/90 mm Hg (34) because the risk for stroke and
CAD in this group was not increased at the previous
lower blood pressure limit (<140/85 mm Hg), as it
is in younger people (35,36). These insights again
highlight that the variants that drive early athero-
genesis are likely to be over-represented among DNA
variants with genome-wide signiﬁcance in GWAS.
Interestingly, the only GWA locus (rs579459) in-
volving blood groups (and the gene ABO) is not linked
to CAD, but is linked to myocardial infarction (37).
Adding weight to our argument that SNPs identiﬁed
by GWAS are generally associated with early CAD
development, this ABO-associated locus is the only
SNP thus far identiﬁed by GWAS associated with
myocardial infarction (obviously a very late event in
CAD development) (37).
For 35 of the 50 candidate genes, their role in
atherosclerosis is unknown. Many, like the suggested
mechanism for the 9p21 locus, appear to involve the
vascular wall, which indicates that they are likely to
be primarily involved in early atherosclerosis devel-
opment. However, perhaps the most compelling evi-
dence for the hypothesis that GWA loci identiﬁed for
CAD primarily reﬂect early atherosclerotic develop-
ment is the lack of hits for inﬂammatory or immune
responses, which are thought to be a central and
causal disease mechanism, particularly for late stages
of atherosclerosis and CAD (38,39). Further support-
ing the notion of late activation, microarray studies of
atherosclerotic lesions during their progression show
activation of inﬂammatory genes predominantly in
the late stages (21). We, therefore, suggest that the
conspicuous absence of inﬂammatory regulators
among currently-identiﬁed genome-wide signiﬁcant
variants for CAD strongly signals that the GWA
approach does not capture the full spectrum of
genetically-driven events of coronary atherosclerosis.
In summary, considerable evidence supports the
notion that genes so far identiﬁed for GWAS loci
predominantly regulate early CAD development.
We expect that the extensive ongoing studies into the
molecularmechanisms of the 46 conﬁrmedGWA-deﬁned
CAD lociwill shed light on this issue, as thesemechanisms
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pathogenesis of atherosclerosis.
SYSTEMS GENETICS—IDENTIFYING
DISEASE-DRIVING NETWORKS AND
THEIR GENETIC REGULATION
The proposed conventions synopsize into early CAD
development being governed by genetic variants
of molecular disease processes that are persistent
and less affected by environmental contexts, as
opposed to those governing later phases of CAD
(Figure 1C). They are consequently more likely to have
surfaced as genome-wide signiﬁcant in GWAS, at least
from how these datasets have been analyzed to date.
A pertinent question then arises: how might one
identify context-dependent DNA variants regulating
disease processes active over a limited time, as in the
rapid expansion and late phases of CAD development,
that are not recognized as genome-wide signiﬁcant
variants in a traditional DNA analysis? As these late
processes are believed to involve many (as opposed to
isolated) causative DNA variants with varying context-
dependence (shifting with microenvironments and
time), we believe that the key lies in ﬁrst deﬁning the
molecular processes driving these later phases in
complex diseases, and then identifying the DNA vari-
ants that causally regulate them, thus allowing their
contribution to heritability to be weighed. By ﬁrst
addressing the molecular underpinnings of variable
complex disease processes, we may be able to unmask
a substantial portion of the missing 90% of the heri-
tability of CAD and other complex diseases.
How can this be best achieved? The increasingly
frequent answer is systems genetics (40–43). To us, the
aim of systems genetics can be summarized as using
genomic activity measures (e.g., ribonucleic acid
[RNA], proteins, metabolites, and DNA modiﬁcations)
to deﬁne disease-driving molecular processes and
integrate them with GWA datasets, thereby permit-
ting their contribution to complex disease heritability
to be understood. However, the ultimate goal must be
to enable diagnosis and treatment of patients on the
basis of the status of these complex disease processes
and to modulate pathological activity toward a non-
pathological state.
It is increasingly understood that individual ge-
netic variants, individual genes, or even linear path-
ways will never explain the intrinsic complexity of
molecular processes underlying common diseases
like CAD. Instead, these processes have polygenetic
regulation and consist of multiple genes interacting in
highly complex, ﬂuid, and dynamic biologic networks
reminiscent of intricate wiring diagrams. Fortunately,biological networks are sparse, with most genes
(nodes) having only a small number of interaction(s)
with other genes (edges), and with only a few highly
interconnected nodes acting as hubs with many edges
(44). These features can be identiﬁed from measures
of genome activity (45). Furthermore, biological net-
works are well-conserved throughout evolution and,
because of built-in redundancy, are biologically
robust to an individual node’s loss (46). In parallel,
technological advances in screening genomes and
genome activity with ever-greater reliability and
lower cost, together with increasing capacities for
computational analysis of large datasets, have set the
stage for more widespread use of systems genetics in
biology, medicine, and health care (17).
Presently, causal disease networks are mostly
inferred from the combination of genotype (DNA) and
gene expression data in genetics of gene expression
studies (GGES) (Figure 3). Although beyond the scope
of this review, this is achieved using network in-
ference algorithms for coexpression (i.e., weighted
coexpression networks analysis), Bayesian probabi-
listic network models (47–50), and direct statistical
tests for causality (51,52). To date, most algorithms are
designed to infer disease networks from gene expres-
sion data generated by microarrays. More recently,
modiﬁed algorithms that also infer biological net-
works from heterogeneous next-generation sequence
datasets (e.g., RNA sequence) are emerging (53).
In our CAD research, we have focused on GGES of
multiple tissues (Central Illustration), namely the
STAGE (Stockholm Atherosclerosis Gene Expression)
(7) and STARNET (Stockholm Tartu Atherosclerosis
Reverse Network Engineering Task) studies. STAGE
was a pilot study for STARNET, with 100 and 900
cases, respectively. Subjects were recruited from pa-
tients undergoing open thorax surgery; those having
coronary artery bypass grafting served as cases, and
those without atherosclerosis or CAD (conﬁrmed by
pre-operative angiography) undergoing other forms
of open thorax surgery (e.g., isolated mitral valve
repair) served as controls.
Parallel sampling of up to 9 CAD-relevant tissues
from each patient is a key aspect of the STAGE and
STARNET studies (7). RNA samples from case and
control subjects were obtained from the arterial wall,
liver, visceral abdominal fat, skeletal muscle, subcu-
taneous fat, primary monocytes, and monocytes
that were differentiated in vitro into macrophages
and foam cells. The 9 RNA samples were then con-
verted into microarray data (STAGE, custom-made
HuRSTA-2a520709 arrays [Affymetrix, Santa Clara,
California]) and, more recently, RNA sequence data
(STARNET). These RNA expression datasets are now
FIGURE 3 Genetics of CAD Gene Expression Studies
A. PATIENT RECRUITMENT
OPEN THORAX CARDIAC
SURGERY
CAD + CABG = Cases
No CAD (eg. MVR) = Control
B. OPEN THORAX SURGERY C. CLINICAL ENDPOINTS
Angiographic CAD-scores
5 year clinical outcomes
D. DATA GENERATION
FROM TISSUES
DNA genotypes
RNA sequence
Biochemical
E. SYSTEMS GENETICS INFERRING CAUSAL
CAD NETWORKS + KEY DISEASE DRIVERS
Network inference using RNA and DNA data
Networks linked to clinical phenotypes
F. INTEGRATE GWA DATASETS
Determine inherited risk enrichment
using GWA dataset of CAD/MI
The STAGE (Stockholm Atherosclerosis Gene Expression) and STARNET (Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task) genetics of gene
expression studies (GGES). (A) Patient recruitment. Patients were included if eligible for coronary artery bypass grafting (CABG) or other non-CAD related indications for
open thorax surgery and had no other severe systemic diseases (e.g., widespread cancer or active systemic inﬂammatory disease). The ethical committees of the
Karolinska and Tartu University Hospitals approved the studies, and patients gave written consent (Dnr 004-02 and 2007/1521-32). (B) Open thorax surgery. Between
7 and 9 vascular and metabolic tissues of 124 (STAGE) and 600 (STARNET) CAD patients and 100 non-CAD control subjects (STARNET), all clinically well-characterized,
were sampled during open thorax surgery as described (7). Ribonucleic acid (RNA) samples were isolated from the atherosclerotic arterial wall, internal mammary artery,
liver, skeletal muscle (Sklm.), subcutaneous (s.c.) and visceral fat, whole blood, and primary blood monocytes differentiated into macrophages and foam cells in vitro.
(C) Clinical endpoints. In each patient, a total of 114 clinical characteristics were screened, including the SYNTAX score (from pre-operative angiograms), which shows
the clinical degree of coronary atherosclerosis. Currently, the 5-year follow-up of mortality (from CAD and other reasons) and CAD-related morbidity is being conducted.
(D) Data generation. GenomeWideSNP_6 arrays (Affymetrix) were used for genotyping DNA, and Custom-made HuRSTA-2a520709 arrays (Affymetrix) were used for
gene expression proﬁling (STAGE) and RNA sequencing (Illumina2500, STARNET). (E) Systems genetic analysis. Gene expression and RNA sequence data are used
to deﬁne groups of genes acting together in modules and networks based on coexpression similarities (17,52,64,65). An eigengene value of each module is calculated
and correlated with the phenotypic characteristics of the patients. For modules with strong phenotypic associations, Bayesian network algorithms are applied to infer
key drivers genes (50,67,68) (yellow nodes) believed to serve as diagnostic markers and therapeutic targets. (F) Integrate GWA datasets. GWA datasets for CAD
are reanalyzed to assess risk enrichment of identiﬁed regulatory gene networks. Abd. ¼ abdominal; MI ¼ myocardial infarction; MVR ¼ mitral valve repair; other
abbreviations as in Figures 1 and 2.
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838used: 1) to infer causal regulatory disease-driving
molecular processes, as reﬂected in gene networks
operating both within and across tissues to cause CAD;
and 2) to identify DNA variants that modulate these
networks (7). We believe that the STAGE/STARNET
datasets are unique in allowing us, for the ﬁrst time to
our knowledge, to study the inherent complexity ofthe molecular process underlying the late, possibly
rapid phases of CAD development across the 9
collected tissues.
Even before inferring gene networks, the STAGE/
STARNET dataset can be used to identify expression
quantitative trait loci (eQTLs) (54–58) in CAD, espe-
cially as related to established GWA loci. An eQTL is a
CENTRAL ILLUSTRATION Systems Genetics to Understand Coronary Artery Disease: Genetics of Genome-Wide
Expression Studies
Björkegren, J.L.M. et al. J Am Coll Cardiol. 2015; 65(8):830–45.
A wide range of genomic (deoxyribonucleic acid [DNA], ribonucleic acid [RNA], protein, and metabolite), clinical, imaging, and prior knowledge data (circles
above the half-circle) are integrated to infer causal gene networks reﬂecting central disease processes in complex diseases. (Left) Genome-wide (GW)
association datasets are integrated in the analysis of these networks to determine their load of inherited risk, which also indicates their level of causality.
(Right) Key drivers in disease-causing networks are analyzed against transcriptomic data from studies of numerous approved and experimental drugs to
identify drugs that either increase or decrease the activity of genes in the network (i.e., drug repurposing; heat map indicates gene activity in a network
exposed to drugs). Identiﬁed drugs can be tested in models of complex disease (e.g., mouse models). The ﬁnal goal is to enable diagnosis and treatment of
patients on the basis of their molecular disease status, reﬂected by the activity status of disease networks. The center parallelogram shows disease-causing
gene networks acting within and across tissues (red indicates atherosclerosis; brown indicates liver; orange indicates skeletal muscle; and blue indicates
fat) that are integrated through communication (e.g., via blood). The central network indicates the presence of cross-tissue networks.
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839DNA variant (frequently an SNP) that regulates gene
expression levels. They are determined by linking
alleles of the SNPs found by genotyping the patient’s
DNA (e.g., in STAGE and STARNET from Affymetrix
GenomeWideSNP_6 arrays) with gene expression
levels from the various tissues. SNP alleles associated
with different levels of gene expression, and there-
fore acting as eQTLs, can then be identiﬁed.Using the STAGE data, we recently identiﬁed 8,156
eQTLs for 6,450 unique genes across 7 CAD-relevant
tissues (59). By integrating the analysis with 2 inde-
pendent GWA datasets for CAD, the Myocardial
Infarction Genetics Consortium (60) and the Well-
come Trust Case Control Cohort (61) to assess the
enrichment of these eQTLs in inherited risk, we
discovered that those eQTLs regulating gene activity
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840across greater numbers of tissues lead to increased
CAD risk. Furthermore, eQTLs that were operative
across several tissues resided at regulatory genomic
“hot spots” (62). In contrast, most of the 22 eQTLs
identiﬁed in the STAGE study that were established
as “CAD GWA hits” affect gene expression in a single
tissue, or, at most, in 2 tissues. In our view, the
multitissue involvement of the risk-enriched eQTLs
suggests that they regulate molecular processes
acting across several of these tissues (63) in late CAD
development and also may be important contributors
to the inherited CAD risk. In contrast, that the 22
STAGE eQTLs were established GWA loci for CAD
regulated genes mostly in 1 or 2 tissues is consistent
with their involvement in early CAD development.
The STAGE/STARNET datasets were next used to
deﬁne groups of genes acting together in modules
and networks, primarily on the basis of similar coex-
pression (17,52,64,65) across the 9 tissues. After
identifying these modules, an important next step is
to link them to relevant patient phenotypes. For
example, we calculated the eigengene value repre-
senting the sum of all gene expression values in a
given module/network (66), which can subsequently
be used to correlate modules with phenotypic char-
acteristics of STAGE and STARNET patients. Gene
modules associated with key CAD phenotypes, such
as the angiographic SYNTAX score (from pre-
operative angiograms) and plasma LDL cholesterol
levels, can thus be identiﬁed. For modules with
strong phenotypic associations, Bayesian network
algorithms or other statistical causal inference tech-
niques are applied, incorporating information on
eQTLs to determine modules that are causally related
to CAD, as opposed to those that are reactive or in-
dependent. The Bayesian networks can also be
employed to infer key driver genes important for
regulating the state of the module (50,67,68), where
they may serve as diagnostic markers, therapeutic
targets, or both (see “Drug Repurposing” section).
Applying a systems genetics approach in clinical
medicine (46) is certainly not limited to DNA geno-
type and RNA expression studies (Central Illustration),
and can include more than 1 targeted tissue (Figure 3)
(69). The more clinical information obtained from the
study subjects the better. Genotype and RNA
expression data can be linked to clinical images and
histology that indicate stages of severity in cancer
development (70,71) and diseases of the central ner-
vous system (72). Genome-wide analyses of proteins,
metabolites, and lipids may also be considered.
Because of their rapid turnover, tissue protein pro-
ﬁles (as opposed to RNA expression) are more vari-
able, and it is now appreciated that protein,metabolite, and lipid analyses are not as well-suited
for systems analyses at the genome-wide level in in-
dividual human tissues, given the current state of the
technology to measure these different dimensions.
However, patterns of protein and metabolite expres-
sion in plasma may be an exception (73,74), and
integrating RNA expression with protein and metab-
olite proﬁles can greatly enhance the predictive po-
wer of disease gene networks (75).
Taking all of the previously-mentioned arguments
into consideration, we advocate a systems biology-
type clinical study design with the basic features out-
lined for STAGE and STARNET, which we have termed
genome-wide network studies (GWNS). In addition to
DNA and careful clinical phenotypes, this would also
include multiple intermediate phenotypes, such as
RNA, proteins, metabolites, and screening of mole-
cules that modify the structures of DNA/RNA/proteins
(that is, epigenetics) in all tissues relevant for the
disease in question. We believe that GWNSwill help us
to understand the molecular mechanisms underlying
genome-wide signiﬁcant loci identiﬁed by GWAS and,
eventually, by WES/WGS. However, perhaps more
importantly, GWNS will help us to identify the variety
and full spectrum of molecular processes driving
complex diseases. We think the way forward is to
establish network models of these processes, both to
uncover the fraction of missing heritability of complex
diseases, and also to eventually establish a new para-
digm of healthcare on the bases of molecular di-
agnostics and individually-tailored therapy.
Importantly, in applying GWNS, or any high-
dimensional data analysis approach to complex
traits, it is important to consider strict statistical
thresholds correcting for multiple testing. For
example, false discovery rate control (a form of sta-
tistical correction for multiple comparisons) should
be used when detecting eQTLs (76) and when
assessing gene network associations (66). Of note, as
opposed to testing individual genes/SNPs in GWAS,
GWNS reduce the problem with multiple testing by 1
to 3 orders of magnitude. Nonetheless, the issue of
multiple testing remains relevant for GWNS.
For network associations (e.g., eigengenes) with
phenotypes, the family-wise false positive rate is
rigorously controlled by empirically estimating the
null distribution of those associations via permuta-
tion testing and then controlling the false discovery
rate by setting an appropriate p value threshold on
the basis of that distribution. The discovery of eQTLs
is similarly assessed by controlling for the false dis-
covery rate. The network itself is a stable structure in
that if we randomize the data so that the correlation
among molecular features is destroyed, no credible
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841network structure results (the resulting network is
not scale-free, no subnetworks/modules are identi-
ﬁed, and so on). Regarding pathway enrichment in
subnetworks, their signiﬁcance in the context of
multiple testing is again assessed by empirically
estimating the distribution of the enrichments in the
context of the network topology, shufﬂing gene
names in the network, but maintaining network to-
pology. On this basis, p value thresholds are set to
control the false discovery rate.
The relative focus of the STAGE and STARNET
studies on the transcriptome (as opposed to the
epigenome/proteome/metabolome) is for several rea-
sons. Besides the limited amount of tissue sample and
superior technology development for RNA screening,
the transcriptome also appears sufﬁciently stable to
capture meaningful variations relating to disease
development. However, protein turnover is far more
rapid, which introduces additional biological vari-
ability such that patient-to-patient comparisons of the
proteome are more challenging. Nonetheless, we are
strong advocates of integrating all types of “-omics”
data in GWN analyses, and have previously shown that
integrating proteome data with the analysis of DNA
and RNA improves the predictive power of the ensuing
networks (67). Therefore, although prone to greater
variability, we believe that the assessment of plasma
proteins remains particularly important for GWNS of
CAD and other complex traits. Systemic integration of
plasma proteins with established roles in CVD (Online
Table 1) (77) and unbiased mass-spectrometry analysis
(78) are currently being performed in plasma from the
STARNET study primarily to identify novel markers
for risk of clinical CAD events and, potentially, for CAD
therapy (79). Similarly, we are working on computa-
tional strategies to integrate genome-wide epigenetic
measures in GWN analyses (80).
Another pertinent question for GWNS is that of
ethnicity. The STAGE and STARNET study participants
are predominantly of northern European ancestry,
which is similar to European American (EAs). But, what
is the relevance of the STARNET GWNS for CAD in Af-
rican Americans (AAs) and Hispanic Americans (HAs)?
CAD risk factors (and thus, with a high degree of cer-
tainty, the networks/pathways in which they operate)
are generally believed to be similar across ethnicities.
This would suggest that the CAD networks to be
inferred from the STARNET datasets should also be
relevant to CAD in AAs and HAs. The frequent, suc-
cessful use of animal models, predominantly mouse,
to study CAD/atherosclerosis suggests that, at least for
the early stages of CAD, many disease pathways are
similar, even across species. Importantly, however,
even if the main CAD risk factors are operative acrossmost or all ethnicities, this is different from stating
that every risk factor is equally important across eth-
nicities. In fact, the relative importance of CAD risk
factors in EAs, AAs, and HAs differs. For example, in-
sulin resistance, hypertension, and obesity are much
more prevalent causes of CAD in AA than in EA (81).
Thus, STARNET should improve our general under-
standing of causal CAD networks and their key drivers.
To decipher the relative roles of these CAD networks in
individual ethnicities, 1 strategy is to examine inheri-
ted risk proﬁles of CAD networks for AA, EA, and HA.
For this, it is necessary to compute CAD network eQTLs
for associations with CAD (risk) using GWA datasets
speciﬁc to these ethnicities (12,82,83) (see part 2 in
“The Role of GWAS in the Era of Systems Genetics”).
Nonetheless, additional GWNS are certainly required
on the basis of study designs similar to those of STAGE
and STARNET, but on non-Caucasians, and preferably
across the entire spectrum of complex disorders.
In this review, we suggest that we are on the verge
of a new era of discovery of the genetics of CAD and
other complex disorders, primarily on the basis of
GWNS and GGES. We therefore strongly advocate that
additional GWNS should be encouraged by funding
bodies, as they hold great promise to decipher com-
plex disease etiologies and represent an alternative
route to extract further meaningful information from
existing GWA datasets.
THE ROLE OF GWAS IN THE ERA OF
SYSTEMS GENETICS
Although GWAS, followed by WES and WGS (“GWA
datasets”), will remain fundamentally important in
the search for the genetic causes of disease, we
believe that integrating these datasets in GWNS pro-
vides a parallel approach for clinical studies that
should help to deﬁne additional genetic regulators of
CAD and other complex diseases. We anticipate that
GWNS may uncover a signiﬁcant portion of the
missing heritability. We suspect that GWA datasets
contain untapped information about the heritability
of complex diseases and that, in the era of systems
genetics, by integrating the analysis of GWNS
with GWA datasets, we can prioritize risk variants
that fail to reach genome-wide signiﬁcance. With this
perspective, we foresee that GWA datasets will be
reutilized in at least the following 3 ways.
1 . Reanalys i s of GWA datasets based on common
r i sk factors for CAD. Reanalyzing GWA datasets
subcategorized on the basis of common risk factors
for CAD is a straightforward, but remarkably
seldom-used, strategy to identify DNA variants for
heritability of complex diseases. For example, a
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for CAD (27) concluded that risk variants identiﬁed
by GWAS can help explain the risk of CAD in
particular subgroups of patients deﬁned by tradi-
tional risk factors. To extend such analyses beyond
risk variants identiﬁed by GWAS, we suggest that
GWA datasets be reanalyzed after subjects are
sorted into groups with and without given risk
factors. The underlying objective is to increase the
likelihood of identifying DNA variants of genome-
wide signiﬁcance in CAD cases with a given risk
factor (e.g., diabetes, hyperlipidemia, or hyper-
tension). Such a strategy would not merely help to
reidentify established CAD risk variants discov-
ered by traditional case-control GWA comparisons,
but will also help to identify risk variants previ-
ously found to be suggestive or to have nominally-
signiﬁcant associations with CAD (Figure 2). The
results might point toward additional molecular
mechanisms important for risk assessment and,
possibly, for therapies for CAD patients with
certain risk factors.
2. Reus ing GWA datasets to deﬁne inher i ted
r i sk-enr ichment of genes be l ieved to be
involved in complex d i sease development .
Another strategy for reusing GWA data is to
consider inherited risk-enrichment analysis of
groups of genes suspected to be associated with
disease (84,85) (Central Illustration). These genes
can either be differentially expressed between
disease and control samples (22) or active in
disease-related modules (7), networks, or pathways
(86–88). Regardless of the gene list origin, the
principal concept is that DNA variants regulating
the genes of interest (eQTLs) should carry
increased association for complex disease (i.e., be
risk-enriched) if they are causally related to the
disease. In brief, SNPs corresponding to the eQTLs,
and highly-correlated SNPs in their immediate vi-
cinity (“the experimental set”), are examined for
disease association in a relevant GWA dataset.
Typically, nominal signiﬁcance (p < 0.05) is chosen
as the threshold for “disease association,” but this
may vary between studies. Next, control sets
(n > 5,000) containing the same number of SNPs as
the experimental set are randomly selected
(located on the same chromosome and in areas with
similar gene density). The fold risk-enrichment is
determined by comparing the number of disease-
associated SNPs in the experimental set with the
average number of disease-associated SNPs in the
control sets. We believe this is an especially
promising technique to evaluate a set of genes for
their relevance to a given disease. In contrast togene ontology or pathway gene enrichment anal-
ysis, the method is data-driven and unbiased. In
addition, a gene set regulated by risk-enriched
eQTLs, according to the GWA dataset, is not
merely involved in disease; the risk-enrichment
also indicates that the genes are causally related
to disease, as opposed to being reactively related.
This strategy’s power has been demonstrated in
studies of type 2 diabetes (89), CAD (59,87,88), and
early-onset Alzheimer’s disease (72).
3 . Reanalys i s of GWA datasets by subcategor ies
deﬁned by the s t a t u s o f d i s e a s e -d r i v i ng
ne two rk s . As we suggested earlier for estab-
lished macroenvironmental risk factors, the status
of disease-driving molecular processes at the
microenvironmental level represented by gene
networks (deﬁned by their gene connectivity and
activity) can be used to assign patients to well-
deﬁned subgroups. These subgroups can then be
used to reanalyze GWA datasets to identify
genome-wide signiﬁcant risk variants associated
with the status of these complex disease processes.
THERAPEUTIC TARGETING OF
CANDIDATE GENES FOR GWA LOCI AND
DRUG REPURPOSING OF KEY DRIVERS IN
DISEASE-DRIVING MOLECULAR NETWORKS
Many research programs are working to understand
the biological mechanisms underlying the genome-
wide signiﬁcant risk variants identiﬁed by GWAS
(90), with the goal of targeting these novel mecha-
nisms therapeutically. Although we believe this
approach will primarily target early CAD processes,
it may also point toward pathways that can be
modulated to affect the disease in its later stages. For
instance, targeting PCSK9 to improve plasma choles-
terol lowering may indeed help reduce risk in patients
with more advanced forms of CAD (91).
Nevertheless, we believe that targeting key drivers
of disease networks will be an equally, or even more,
successful strategy. For this purpose, we developed
an integrated informatics approach to systema-
tically screen genome-wide transcriptional signatures
of drug perturbation (treated vs. untreated) from the
public domain (e.g., Connectivity Map [92]) against
genome-wide transcriptional signatures of disease
states (on up to networks) to identify repurposing
candidates (93,94). Drug screening approaches
typically require knowledge of drug target proﬁles
or mechanisms of action, which is often lacking.
In contrast, our approach requires no knowledge of
the mechanism of action and can consider the
system-wide properties of drug-induced molecular
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843perturbations (e.g., genome-wide transcriptional
changes) to enable discovery of novel connections
between drugs and disease states through a data-
driven approach (94). This approach also allows for
rational repurposing of multitarget compounds (pol-
ypharmacology) that might exhibit therapeutic ef-
fects against a complex disease like CAD through
modulation of multiple network driver nodes (90).
The broad biological relevance of this approach is
supported by experimental validation of several
novel drug indications identiﬁed by a computational
drug-repurposing pipeline. This system was recently
used to transcriptionally proﬁle intestinal samples
obtained from inﬂammatory bowel disease (IBD) pa-
tients to experimentally validate a novel IBD indica-
tion predicted for the anticonvulsant agent,
topiramate (94). Topiramate has no history of efﬁca-
cious use for IBD or other inﬂammatory diseases.
There are no established therapeutic targets for IBD
or other inﬂammatory diseases among the canonical
targets of topiramate, which enhances GABA-A re-
ceptor activity, antagonizes AMPA/kinate glutamate
receptor subtypes, and weakly inhibits carbonic
anhydrase isozymes II and IV (93). In a rodent model
of IBD induced with 2,4,6-trinitrobenzenesulfonic
acid, topiramate signiﬁcantly reduced the severity of
IBD, as judged by gross pathophysiological and his-
topathological measures (94).
In a separate study (95), this computational drug-
repurposing approach was applied to transcriptional
proﬁles of tumor versus adjacent normal tissue to
identify novel drug-repurposing candidates for small-
cell lung cancer (SCLC). Several pharmacologically-
diverse compounds were identiﬁed as novel
drug-repurposing candidates for SCLC, including: the
tricyclic antidepressant, imipramine; the calcium-
channel blocker, bepridil; and the phenothiazine
antihistamine, promethazine. Anti-SCLC or other
antineoplastic effects were not previously established
for these drugs or for other drugs of the same phar-
macological class. The anti-SCLC activity of these
compounds was validated in experiments in human
and animal model systems in vitro and in vivo (95).
In summary, given the shortage of new drugs
reaching the market for CAD and many other complex
diseases, drug repurposing, using a systems genetics
approach to deﬁne new agents and novel indications
for existing therapies, will be an essential path to-
ward personalized and preventive drug therapies.
SUMMARY AND FUTURE DIRECTIONS
To answer our own question posed in the title of this
paper, there is no doubt that GWAS are important inproviding datasets to reveal risk variants that explain
the heritability of complex diseases. In particular,
genome-wide signiﬁcant loci point to potentially
important genes and molecular mechanisms respon-
sible for the pathobiology of these diseases. How-
ever, we believe that traditional analyses of GWA
datasets overlook the potential role of context-
dependent risk variants that exert risk only when
certain environmental inﬂuences are operative.
These inﬂuences typically arise over a shorter period
and, increasingly, at later stages of disease develop-
ment. We believe these context-dependent risk var-
iants can have a large effect on key disease processes
active during limited windows of complex disease
development. As such, they are unlikely to emerge
in traditional GWA dataset analyses as of genome-
wide signiﬁcance, but are likely to be detected as
suggestive or nominally-signiﬁcant risk variants. If
this is the case, much information on the heritability
of complex disease remains hidden in GWA datasets.
We believe that, by applying GWNS to identify the
disease-driving molecular processes reﬂected in
molecular networks and their genetic regulators,
this information can be revealed. We propose that
these disease-driving gene networks can distinguish
true- from false-positive risk variants with nominal
disease associations in GWAS. As more network
biology underlying complex disorders is revealed,
the relevant activity and type of disease network can
be used as a diagnostic marker to subcategorize
patients into groups requiring different therapeutic
measures. To reach this goal, we must enter a post-
GWAS era, in which priority is given to clinical
studies that include intermediate phenotypes (with
the general design described earlier for GWNS, but
also considering other genome-wide measures be-
sides RNA) and where the screening of patients
ranges from gross disease phenotypes (i.e., CAD), to
histological and image-based patient characteristics,
and ultimately to clinical outcomes. Such studies will
be essential for solving the puzzle of interconnected
molecules (e.g., genes) in disease-driving networks,
perhaps allowing fulﬁllment of the long-sought goal
of the “genomic revolution”: the preventive and
individual care of patients in molecularly-deﬁned
subcategories.
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